Drug Type Small molecule drug |
Synonyms APL 1202, APL-1202, 5-Nok + [10] |
Target |
Mechanism METAP2 inhibitors(Methionine aminopeptidase 2 inhibitors), Angiogenesis inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC9H6N2O3 |
InChIKeyRJIWZDNTCBHXAL-UHFFFAOYSA-N |
CAS Registry4008-48-4 |
Start Date26 Jun 2024 |
Sponsor / Collaborator [+1] |
Start Date06 May 2024 |
Sponsor / Collaborator |
Start Date10 Nov 2022 |
Sponsor / Collaborator- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D07245 | Nitroxoline |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Bladder Cancer | Phase 3 | CN | 04 Nov 2020 | |
Non-Muscle Invasive Bladder Neoplasms | Phase 3 | CN | 30 Mar 2017 | |
Muscle Invasive Bladder Carcinoma | Phase 2 | US | 02 Dec 2021 | |
Prostatic Cancer | Phase 1 | CN | - | |
Amebiasis | IND Approval | CN | 24 Jun 2024 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
Phase 2 | Bladder Cancer Neoadjuvant | 42 | odrkkpqbqe(wvevmqbjxs) = revcfrnunq phnkwcsauk (byxbgkzcxg ) View more | Positive | 25 Jan 2024 | ||
odrkkpqbqe(wvevmqbjxs) = inzrrhrcly phnkwcsauk (byxbgkzcxg ) View more |